Irbesartan Stada (Irbesartan)

Irbesartan works by selectively blocking angiotensin II type 1 (AT1) receptors. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone release, leading to relaxed blood vessels, reduced sodium and water retention, and ultimately lower blood pressure and renal protection.

The specific dose of Irbesartan Stada is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Irbesartan is generally contraindicated during the second and third trimesters of pregnancy because it may cause fetal harm. Safety during breastfeeding has not been established, so the medication should be used only if the potential benefit justifies the potential risk to the infant.

To place an order, submit an enquiry on the Irbesartan Stada product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to Irbesartan is the ACE‑inhibitor class (e.g., enalapril). Both lower blood pressure by targeting the renin‑angiotensin system, but ARBs like Irbesartan are less likely to cause a persistent dry cough and have a lower incidence of angioedema, making them a preferred option for some patients.

Irbesartan tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Irbesartan is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or split the tablet unless instructed.

Serious risks include angioedema (swelling of the face, lips, tongue, or throat), severe hypotension (dangerously low blood pressure), acute kidney injury, and significant hyperkalemia (high potassium levels). Patients should seek immediate medical attention if they experience any of these symptoms.

Irbesartan should not be used by individuals with known hypersensitivity to the drug or any of its components, patients with severe hepatic impairment, or women who are pregnant, especially in the second and third trimesters. Caution is also advised for patients with existing kidney disease or elevated potassium levels.